STOCK TITAN

BrainsWay to Present at the Oppenheimer 31st Annual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

BrainsWay Ltd. (NASDAQ: BWAY) has announced that Christopher von Jako, CEO, will present at the Oppenheimer 31st Annual Healthcare Conference from March 16-18, 2021. The presentation is scheduled for 10:00 AM ET on March 16, 2021. Investors can also participate in one-on-one meetings during the event. BrainsWay specializes in non-invasive neurostimulation products, having received FDA marketing authorization for treatments targeting major depressive disorder, obsessive-compulsive disorder, and smoking addiction.

Positive
  • None.
Negative
  • None.

CRESSKILL, N.J. and JERUSALEM, March 08, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced that Christopher von Jako, Ph.D., President and Chief Executive Officer, will present at the Oppenheimer 31st Annual Healthcare Conference taking place on March 16-18, 2021. The Company will also host one-on-one investor meetings at the conference.

Details on the presentation can be found below.

Date:Tuesday, March 16, 2021
Time:10:00 AM ET
Webcast Link:https://wsw.com/webcast/oppenheimer9/bway/2729199

About BrainsWay
BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neurostimulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology. The Company received marketing authorization from the U.S. Food and Drug Administration (FDA) for its products for a variety of patient populations, including in 2013 for patients with major depressive disorder (MDD), in 2018 for patients with obsessive-compulsive disorder (OCD), and in 2020 for patients with smoking addiction. BrainsWay is currently conducting clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders.

Contacts:
BrainsWay:
Hadar Levy
SVP and General Manager
HadarL@brainsway.com

Investors:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com        


FAQ

When is BrainsWay's presentation at the Oppenheimer Healthcare Conference?

BrainsWay's presentation is scheduled for March 16, 2021, at 10:00 AM ET.

Who will present for BrainsWay at the conference?

Christopher von Jako, Ph.D., President and CEO, will present for BrainsWay.

What does BrainsWay focus on?

BrainsWay focuses on developing and selling non-invasive neurostimulation products using its Deep TMS technology.

What FDA approvals has BrainsWay received?

BrainsWay has received FDA approval for treatments of major depressive disorder, obsessive-compulsive disorder, and smoking addiction.

Where can I access the BrainsWay presentation?

The presentation can be accessed via the webcast link: https://wsw.com/webcast/oppenheimer9/bway/2729199.

Brainsway Ltd. American Depositary Shares

NASDAQ:BWAY

BWAY Rankings

BWAY Latest News

BWAY Stock Data

187.08M
16.17M
19.22%
0.23%
Medical Devices
Healthcare
Link
United States of America
Jerusalem